Evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Test and Identification of Rare Polymorphisms Potentially Affecting Assay Performance
- 1 August 2010
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 48 (8) , 2852-2858
Abstract
We evaluated the FDA-approved Roche Cobas AmpliPrep/Cobas TaqMan (CAP/CTM) HIV-1 viral load assay for sensitivity, reproducibility, linearity, HIV-1 subtype detection, and correlation to the Roche Amplicor HIV-1 monitor test, version 1.5 (Amplicor). The limit of detection calculated by probit analysis was 23.8 copies/ml using the 2nd International WHO Standard and 30.8 copies/ml using Viral Quality Assurance (VQA) standard material. Serial dilutions of six patient samples were used to determine inter- and intra-assay reproducibility and linearity, which were very good (10 copies/ml). Subtype detection was evaluated in the CAP/CTM, Amplicor, and Bayer Versant HIV-1 bDNA 3.0 (Versant) assays using a commercially available panel. Versant averaged 0.829 log 10 copies/ml lower than CAP/CTM and Amplicor averaged 0.427 log 10 copies/ml lower than CAP/CTM for the subtype panel. Correlation with samples previously tested by Amplicor was excellent ( R 2 = 0.884; average difference [Amplicor value minus CAP/CTM value], 0.008 log 10 copies/ml). Of the 305 HIV samples tested, 7 samples generated CAP/CTM titers between 1.0 and 2.75 log 10 copies/ml lower than those for Amplicor. Three of these samples revealed primer and probe mismatches that could account for the discrepancies. Otherwise, the CAP/CTM assay exhibits excellent sensitivity, dynamic range, reproducibility, and correlation with Amplicor in an automated format.Keywords
This publication has 16 references indexed in Scilit:
- Clinical and Resistance Consequences of Misquantification of Plasma and Cerebrospinal Fluid Human Immunodeficiency Virus Type 1 (HIV-1) RNA in Samples from an HIV-1 Subtype G-Infected PatientJournal of Clinical Microbiology, 2009
- Evaluation of the Abbott Investigational Use Only RealTime HIV-1 Assay and Comparison to the Roche Amplicor HIV-1 Monitor Test, Version 1.5The Journal of Molecular Diagnostics, 2009
- Single-Point Mutations Causing More than 100-Fold Underestimation of Human Immunodeficiency Virus Type 1 (HIV-1) Load with the Cobas TaqMan HIV-1 Real-Time PCR AssayJournal of Clinical Microbiology, 2009
- Performance of Three Commercial Viral Load Assays, Versant Human Immunodeficiency Virus Type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, Testing HIV-1 Non-B Subtypes and Recombinant VariantsJournal of Clinical Microbiology, 2008
- Comparative Evaluation of the Automated Roche TaqMan Real-Time Quantitative Human Immunodeficiency Virus Type 1 RNA PCR Assay and the Roche AMPLICOR Version 1.5 Conventional PCR AssayJournal of Clinical Microbiology, 2007
- Human Immunodeficiency Virus Type 1 (HIV-1) Plasma Load Discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 AssaysJournal of Clinical Microbiology, 2007
- Comparison of the Roche COBAS Amplicor™ Monitor, Roche COBAS Ampliprep™/COBAS Taqman™ and Abbott RealTime™ Test assays for quantification of hepatitis C virus and HIV RNAClinical Chemistry and Laboratory Medicine (CCLM), 2007
- Comparison of the LCx Human Immunodeficiency Virus (HIV) RNA Quantitative, RealTime HIV, and COBAS AmpliPrep-COBAS TaqMan Assays for Quantitation of HIV Type 1 RNA in PlasmaJournal of Clinical Microbiology, 2006
- Failure to detect a non-B HIV-1 subtype by the HIV-1 Amplicor Monitor test, version 1.5AIDS, 2003
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986